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Abstract
Background: Serologic detection of Zika virus (ZIKV) infections is challenging because of antigenic similarities
among flaviviruses.
Objective: To evaluate the sensitivity and specificity of commercial ZIKV IgM and IgG enzyme-linked immunoassay
(ELISA) kits.
Methods: We used sera from febrile patients with RT-PCR-confirmed ZIKV infection to determine sensitivity and
sera from RT-PCR-confirmed dengue cases and blood donors, both of which were collected before ZIKV epidemics
in Brazil (2009–2011 and 2013, respectively) to determine specificity.
Results: The ZIKV IgM-ELISA positivity among RT-PCR ZIKV confirmed cases was 0.0% (0/14) and 12.5% (1/8) for
acute- and convalescent-phase sera, respectively, while its specificity was 100.0% (58/58) and 98.3% (58/59) for
acute- and convalescent-phase sera of dengue patients, and 100.0% (23/23) for blood donors. The ZIKV IgG-ELISA
sensitivity was 100.0% (6/6) on convalescent-phase sera from RT-PCR confirmed ZIKV patients, while its specificity
was 27.3% (15/55) on convalescent-phase sera from dengue patients and 45.0% (9/20) on blood donors’ sera. The
ZIKV IgG-ELISA specificity among dengue confirmed cases was much greater among patients with primary dengue
(92.3%; 12/13), compared to secondary dengue (7.1%; 3/42).
Conclusions: In a setting of endemic dengue transmission, the ZIKV IgM-ELISA had high specificity, but poor
sensitivity. In contrast, the ZIKV IgG-ELISA showed low specificity, particularly for patients previously exposed to
dengue infections. This suggests that this ZIKV IgM-ELISA is not useful in confirming a diagnosis of ZIKV infection in
suspected patients, whereas the IgG-ELISA is more suitable for ZIKV diagnosis among travelers, who reside in areas
free of flavivirus transmission, rather than for serosurveys in dengue-endemic areas.
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Background
Zika virus (ZIKV) is an emerging mosquito-borne flavivi-
rus. Majority of human infections evolve asymptomatically
or cause mild and self-limited clinical manifestations.
Non-specific signs and symptoms may include exanthema,
low-grade fever, conjunctivitis, and arthralgia [1–3].
However, following ZIKV outbreaks in French Polynesia
and Brazil, increase in cases of Guillain-Barré syndrome in
adults and of congenital abnormalities in newborns were
identified, and subsequent studies confirmed ZIKV infec-
tion during pregnancy as a cause of congenital neuro-
logical abnormalities [4, 5].
Due to the similarity in the initial clinical presentation
between ZIKV infections and other infectious diseases,
especially with other arboviral diseases that usually
co-occur in tropical and sub-tropical regions, such as
dengue (DENV) and chikungunya (CHIKV), clinical
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diagnosis is challenging, and often depends on labora-
tory confirmation. However, ZIKV laboratory diagnosis
is difficult because viremia tends to be low [6]. In
addition, ZIKV presents structural similarities with other
flaviviruses, especially DENV, resulting in cross-reactive
antibodies [1, 7]. Consequently, serological tests for
ZIKV may cross-react with DENV, particularly when
pre-existing immunity to DENV is present [7–10].
A correct differential diagnosis between ZIKV and
other arboviral infections is critical to alert patients and
clinicians for potentially evolving complications, as well
as to guide appropriate supportive care (i.e. fluid re-
placement for severe dengue patients). In addition, an
accurate ZIKV laboratory diagnosis can inform surveil-
lance activities, which include detection and monitoring
of virus circulation, estimation of disease burden, guid-
ing preventive and control actions to interrupt virus
transmission, and informing pregnant women on the
risk of a gestational infection.
Objectives
In this study, we evaluated the diagnostic sensitivity of com-
mercial enzyme-linked immunoassays (ELISAs) (Euroim-
mun, Lübeck, Germany) for detection of ZIKV IgM and
IgG antibodies in sera of febrile patients with ZIKV infec-
tions. We also assessed the specificity of these kits in sera
of both dengue-confirmed patients and blood donors.
Study design
Study site and design
This study was conducted and reported according to the
STARD (Standards for Reporting of Diagnostic Accuracy)
guideline [11]. The performance of the IgM- and
IgG-ELISAs was evaluated using serum collections from
clinical-epidemiological studies conducted in Salvador,
northeast Brazil. Since DENV introduction in Salvador in
1995, the city has experienced periodic DENV epidemics
[12]. Between 2011 and 2016, approximately 7000 dengue
cases per year were reported in Salvador [13], but the ac-
tual disease burden has been estimated to be at least 12
times greater [14]. In early 2015, Salvador faced a large
outbreak of acute exanthematous illness later attributed to
ZIKV, with over 17,000 reported cases [3, 4].
Most of the serum samples used for our diagnostic test
evaluation were obtained from an acute febrile illness
(AFI) enhanced surveillance study that we conducted in
a public emergency health unit of Salvador, between
January 2009 and August 2016. Details were previously
described [15]. Briefly, the surveillance study enrolled
patients ≥5 years of age with reported fever or measured
axillary temperature ≥ 37.8 °C of up to 7 days of dur-
ation. Self-reported data on days of symptoms and clin-
ical characteristics were obtained from participants at
enrollment.
We collected blood samples from participants at study
enrollment (acute-phase sample) and ≥ 15 days
post-enrollment (convalescent-phase sample). Sera were
stored in aliquots at − 20 °C and − 70 °C for serologic and
molecular testing, respectively. Acute-phase samples were
tested for DENV by NS1- and IgM-ELISA (Panbio Den-
gue Early ELISA and Panbio Dengue IgM Capture, Panbio
Diagnostics, Brisbane, Australia) and convalescent-phase
samples by IgM-ELISA (Panbio Dengue IgM Capture,
Panbio Diagnostics, Brisbane, Australia). Between 2009
and 2014, acute-phase samples that yielded a positive re-
sult in either ELISA underwent RNA extraction (Maxwell®
16 Total RNA Purification kit by Promega, Wisconsin,
USA, or QIAmp® Viral RNA mini kit by Qiagen, Hilden,
Germany) and RT-PCR (AccessQuick RT-PCR System,
Promega, Madison,WI) for dengue typing [16]. Beginning
in 2014, however, all acute-phase samples underwent
RT-PCRs for DENV [16], ZIKV [17] and CHIKV [18].
Dengue IgG-ELISA (Panbio Dengue IgG Indirect ELISA,
Panbio Diagnostics, Brisbane, Australia) was performed
for all acute-phase serum samples of dengue-confirmed
cases; those with a negative result were considered a pri-
mary dengue infection, whereas those with a positive re-
sult were considered secondary dengue infections.
Additionally, we obtained sera from presumably health
volunteer blood donors at the State Blood Donation
Center located in Salvador during December 2013. Col-
lection of blood was performed after the regular screen-
ing process (which, among others, excludes donors
reporting fever in the previous 15 days). Blood donors’
sera were stored in − 20° and subsequently tested for
DENV with the same NS1-, IgM- and IgG-ELISA kits.
Sample selection
To determine the sensitivity of the ZIKV IgM- and
IgG-ELISA (Anti-Zika Virus IgM ELISA and Anti-Zika
Virus IgG ELISA, EUROIMMUN, Lübeck, Germany), we
tested the available sera (14 acute-phase and 8
convalescent-phase serum samples) for the 14 patients
enrolled during the surveillance study who had a ZIKV
infection confirmed by RT-PCR (all of them recruited
between May and July, 2015). To determine the specificity
of the ZIKV IgM- and IgG-ELISA in a group of confirmed
dengue patients, we selected from RT-PCR-positive
dengue cases detected during the AFI surveillance study
the first 20 cases positive for each DENV serotype. We se-
lected the first 20 confirmed cases of each DENV type to
ensure that there was no recognized ZIKV transmission in
Salvador at the time, such that there was limited chance of
a prior ZIKV infection. The selected DENV1-confirmed
patients were detected from April 2009 to May 2011; the
DENV2 from February 2009 to February 2010; and
DENV4 from October 2010 to April 2011. DENV-3 pa-
tients were not selected for testing because we confirmed
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only a very small number of such cases during the study
period. To augment the confidence that these DENV pa-
tients did not have a concomitant ZIKV infection, we also
performed ZIKV RT-PCR on their acute-phase serum
samples. We also determined the specificity of the ZIKV
IgM- and IgG-ELISA in randomly selected sera from 23
blood donors. The initially planned number of samples
from DENV-confirmed patients and blood donors (143
samples: 60 DENV acute- and convalescent-phase samples
each and 23 blood donor samples) was defined to provide
95% confidence for an estimated specificity of 95% and a
precision of ~ 3.5%.
Zika IgM- and IgG-ELISA testing
The ZIKV IgM-ELISA (El 2668–9601 M) and ZIKV
IgG-ELISA (El 2668–9601 G) by Euroimmun (Lübeck,
Germany) were performed according to the manufacturer’s
instructions for semiquantitative interpretations. Although
assay performers were not blinded to group identification
of tested samples (ZIKV, DENV, or blood donors), reading
was performed by automated microplate reader (TECAN,
Maennedorf, Switzerland). Positive and negative controls
were provided by the test’s manufacturer.
Data analysis
The AFI patients with a RT-PCR-based diagnosis of ZIKV
or DENV were characterized according to demographic
characteristics (sex and age) and clinical manifestations.
We calculated the accuracy of ZIKV IgM- and IgG-ELISA
tests, with respective 95% confidence intervals, using the
samples from RT-PCR-confirmed cases of ZIKV infection
as the reference group of positives for sensitivity estima-
tion, and the samples from RT-PCR-confirmed dengue
cases, as well as blood donors as reference groups of nega-
tives for specificity estimation. We also calculated the spe-
cificity among dengue-confirmed cases stratified by the
infecting DENV type and by the type of infection (primary
versus secondary). Samples with equivocal ELISA results
were excluded from the accuracy analysis.
Results
Participants characteristics
The 14 RT-PCR-confirmed Zika cases had a median age of
22.5 years and 42.9% were male. The most frequent clinical
manifestations were headache (92.9%), myalgia (85.7%),
retro-orbital pain (71.4%), rash (71.4%), and pruritus
(71.4%) (Table 1). Median time between symptoms onset
and acute- and convalescent-phase blood collection was
2.5 and 27 days, respectively (Table 1). The 60
RT-PCR-confirmed dengue cases had a median age of
18 years and 51.6% were male. The most frequent clinical
manifestations were headache (96.7%), myalgia (76.7%),
retro-orbital pain (56.7%), and arthralgia (46.7%) (Table 1).
Contrasting with the Zika cases, only 10.0% of the dengue
cases presented with rash. The median time between onset
of symptoms and acute- and convalescent-phase blood col-
lection was 2 and 27 days, respectively (Table 1). The
RT-PCR-positive dengue cases were also positive by
NS1-ELISA (10 patients), by NS1- and IgM-ELISA in the
acute-phase sera (6 patients), by IgM-ELISA seroconver-
sion between acute- and convalescent-phase sera (23 pa-
tients), and by NS1-ELISA and IgM-ELISA seroconversion
(21 patients). Of the 60 RT-PCR-positive dengue cases, 47
had available serum to test by ZIKV RT-PCR and all of
them (100.0%) were ZIKV negative.
For the Zika and dengue cases, the blood sample avail-
ability for ZIKV IgM- and IgG-ELISAs testing are also
summarized in Table 1. The median age for the 23 blood
donors was 32 years and 69.6% were male. All blood do-
nors tested negative by dengue NS1- and IgM-ELISA,
and 20 (87.0%) tested positive by DENV IgG-ELISA.
ZIKV IgM-ELISA performance
As expected, none of the 14 acute-phase samples of
RT-PCR-confirmed Zika cases yielded a positive result in
the ZIKV IgM-ELISA, whereas one of 8 convalescent-phase
samples was positive (12.5% sensitivity; Table 2). Zika
IgM-ELISA yielded a positive result in only one of the 140
non-Zika sera tested (99.3% specificity overall; Table 2).
None of the blood donors and acute-phase sera from
dengue cases tested positive in the ZIKV IgM-ELISA (100%
specificity in both groups). Among the convalescent-phase
sera from dengue cases, only one (from a patient with a pri-
mary infection with DENV-2) tested positive in the ZIKV
IgM-ELISA (98.3% specificity).
Zika IgG-ELISA performance
Of the 14 RT-PCR-confirmed Zika cases, 13 had had
their acute-phase sera tested with the ZIKV IgG-ELISA
and 6 (46.1%) were positive, 4 (30.8%) negative, and 3
(23.1%) equivocal (Table 3). All the 8 convalescent-phase
samples from RT-PCR-confirmed Zika cases tested with
the ZIKV IgG-ELISA were positive, yielding 100% sensi-
tivity (Table 3). Among convalescent-phase sera from
confirmed dengue cases, ZIKV IgG-ELISA yielded posi-
tive results in 40 (66.7%) samples, negative results in 15
(25.0%) samples, and equivocal results in 5 (8.3%) sam-
ples. Among the 23 sera from blood donors, 11 (47.8%)
were positive in the ZIKV IgG-ELISA, 9 (39.1%) were
negatives, and 3 (13.0%) generated equivocal results.
Overall, the specificity of the ZIKV IgG-ELISA for the
75 samples with valid results was 32.0%. The specificity
for convalescent-phase samples of dengue patients was
27.3%, ranging for 5.9% in DENV-4 infections to 45.0%
in DENV-1 infections (Table 3). The specificity was
much lower for patients diagnosed secondary DENV in-
fections (7.1%) compared to those with primary DENV
infections (92.3%). Specificity of the Zika IgG-ELISA
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among blood donors was 45.0%. All 11 blood donors’
samples for which the ZIKV IgG-ELISA returned a posi-
tive result had anti-dengue IgG antibodies, as did 6 of
the 9 blood donors samples that were negative on the
ZIKV IgG-ELISA. The mean optical density value found
on the DENV IgG-ELISA of blood donors with positive
results on the ZIKV IgG-ELISA was 2.738 (standard de-
viation [SD]: 0.179, min. 2.307, max. 2.965), a value sta-
tistically greater than the mean found on blood donors
with negative results on the ZIKV-IgG-ELISA (1.549,
SD: 1.283, min. 0.036, max. 2.873; Wilcoxon rank-sum
test P = 0.04).
Discussion
In this study, we evaluated the diagnostic performance of
commercial IgM- and IgG-ELISAs for serodiagnosis of
Zika virus infection. We used a set of sera collected from
AFI patients prospectively enrolled in an enhanced sur-
veillance study designed to detect arboviral infections,
rather from a reference laboratory serum sample collec-
tion. Thus, we were able to characterize the clinical mani-
festations of the patients providing the sera tested, and to
evaluate the accuracy of the tests in a group of patients’
samples that represent a realistic epidemiologic situation.
Of note, clinical manifestations of RT-PCR-confirmed
Zika and dengue AFI patients were similar, with the ex-
ception of rash, which was most commonly reported
among Zika patients, reinforcing the difficulties in clinic-
ally differentiating these arboviral infections.
We found a high specificity for the Euroimmun ZIKV
IgM-ELISA among both dengue-infected and blood donor
control groups. Specificity among dengue controls was not
affected by infecting serotype or prior dengue infection sta-
tus. However, the sensitivity of the ZIKV IgM-ELISA was
low for either acute- or convalescent-phase serum samples
of Zika febrile patients (0.0 and 12.5%, respectively). As the
time elapsed between Zika symptoms onset and
acute-phase serum collection was short (median 2.5 days),
Table 1 Demographics, clinical characteristics, and serum sample availability for 14 Zika and 60 dengue cases confirmed by RT-PCR
Characteristics Zika cases (N = 14) Dengue cases (N = 60)
Number (%) or median (interquartile range)
Demographic
Male 6 (42.9) 31 (51.7)
Age 22.5 (15–41) 18 (10–34)
Clinical Manifestations
Headache 13 (92.9) 58 (96.7)
Myalgia 12 (85.7) 46 (76.7)
Retro-orbital pain 10 (71.4) 34 (56.7)
Arthralgia 8 (57.1) 28 (46.7)
Vomit 2 (14.3) 12 (20.0)
Rash 10 (71.4) 6 (10.0)
Pruritus 10 (71.4) NA
Prior dengue infectiona
No 1 (8.3) 13 (21.7)
Yes 11 (91.7) 47 (78.3)
Blood sample collected
Acute-phase sample 14 (100) 60 (100)
Time between symptoms onset and sample collection 2.5 (2–4) 2 (1–3)
Convalescent-phase sample 8 (57.1) 60 (100)
Time between symptoms onset and sample collection 27 (18.5–43.5) 27 (19.5–57.5)
Sera tested by ZIKV ELISAb
ZIKV IgM-ELISA in acute-phase sera 14 (100) 58 (96.7)
ZIKV IgM-ELISA in convalescent-phase sera 8 (57.1) 59 (98.3)
ZIKV IgG-ELISA in acute-phase sera 13 (92.9) NT
ZIKV IgG-ELISA in convalescent-phase sera 8 (57.1) 60 (100)
NT = Not tested
aPrior dengue infection was determined by a positive result in the DENV IgG-ELISA performed in the acute-phase serum sample
bSome patients did not have their acute- or convalescent serum sample tested for ZIKV because of insufficient volume of sera
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a low IgM detection in the acute-phase sample was ex-
pected. However, even for the convalescent-phase serum
samples, collected on average 3–6 weeks after disease onset,
the ZIKV IgM-ELISA yielded a low sensitivity. This low
performance was also reported for RT-PCR-confirmed Zika
samples from residents from other ZIKV- and
DENV-endemic areas (Suriname, Dominican Republic and
Colombia), where Euroimmun Zika IgM-ELISA detected 6
of the 19 evaluated samples collected ≥1 days post onset of
symptoms (dpos) and 5 of 12 samples collected ≥6 dpos,
yielding sensitivities of 31.6 and 41.7%, respectively [19].
Interestingly, the same study reported sensitivities of 87.5
and 100.0% among RT-PCR-confirmed Zika samples from
returning travelers with ≥1 dpos and ≥ 6 dpos, respectively,
suggesting that previous flavivirus infections may alter
ZIKV antibody responses.
Although recent studies suggest a high specificity of
this Zika IgG-ELISA against dengue infections in
Table 3 Performance of the Euroimmun ZIKV IgG-ELISA kit
Performance according to the type of serum samples ZIKV IgG-ELISA result % (95% CI)
Sensitivity Positive Negative
Acute-phase samples of RT-PCR-confirmed Zika casesa 6 4 40.0 (12.2–73.8)
Convalescent-phase samples of RT-PCR-confirmed Zika cases 8 0 100.0 (63.1–100.0)
Specificity Negative Positive
Convalescent-phase samples of RT-PCR-confirmed dengue casesb 15 40 27.3 (16.1–41.0)
Samples of DENV-1 infected cases 9 11 45.0 (23.1–68.5)
Samples of DENV-2 infected cases 5 13 27.8 (9.7–53.5)
Samples of DENV-4 infected cases 1 16 5.9 (0.2–28.7)
Samples of primary dengue cases 12 1 92.3 (64.0–99.8)
Samples of secondary dengue cases 3 39 7.1 (1.5–19.5)
Blood donors samplesc 9 11 45.0 (23.1–68.5)
aOf the 14 acute-phase serum samples from RT-PCR confirmed Zika cases, 1 was not tested by the ZIKV IgG-ELISA because of insufficient sample volume and 3
presented equivocal results and were not included in this analysis
bOf the 60 convalescent-phase serum samples from dengue cases tested with the ZIKV IgG-ELISA, 5 presented equivocal results and were not included in
this analysis
cOf the 23 serum samples from blood donors tested with the ZIKV IgG-ELISA, 3 presented equivocal results and were not included in this analysis
Table 2 Performance of the Euroimmun ZIKV IgM-ELISA kit
Performance according to the type of serum samples ZIKV IgM-ELISA result % (95% CI)
Sensitivity Positive Negative
Acute-phase samples of RT-PCR-confirmed Zika casesa 0 14 0.0 (0.0–23.2)
Convalescent-phase samples of RT-PCR-confirmed Zika cases 1 7 12.5 (0.3–52.7)
Specificity Negative Positive
Acute-phase sample of RT-PCR-confirmed dengue cases 58 0 100.0 (93.8–100.0)
Samples of DENV-1 infected cases 19 0 100.0 (82.4–100.0)
Samples of DENV-2 infected cases 19 0 100.0 (82.4–100.0)
Samples of DENV-4 infected cases 20 0 100.0 (83.2–100.0)
Samples of primary dengue cases 13 0 100.0 (75.3–100.0)
Samples of secondary dengue cases 45 0 100.0 (92.1–100.0)
Convalescent-phase sample of RT-PCR-confirmed dengue cases 58 1 98.3 (90.9–100.0)
Samples of DENV-1 infected cases 20 0 100.0 (83.2–100.0)
Samples of DENV-2 infected cases 18 1 94.7 (74.0–99.9)
Samples of DENV-4 infected cases 20 0 100.0 (83.2–100.0)
Samples of primary dengue cases 12 1 92.3 (64.0–99.8)
Samples of secondary dengue cases 46 0 100.0 (92.3–100.0)
Blood donors samples 23 0 100.0 (85.2–100.0)
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returning travelers [19–22], we have demonstrated an
overall low performance in a dengue-endemic region.
This may be due to a greater frequency of secondary
DENV infections in the population we studied (78.3%),
in which specificity was 7.1% contrasting with 92.3% in
primary infections. The low specificity of the Zika
IgG-ELISA among our blood donor control group may
be also explained by the high frequency (87.0%) of
DENV IgG antibodies observed in this group. We also
found a large difference in the ZIKV IgG-ELISA specifi-
city among DENV-confirmed samples according to
DENV serotype, varying from 5.9% in DENV4-infected
patients to 45.0% in DENV1-infected patients. This dif-
ference is likely explained by the prior dengue-immune
status of these patients, since 100% of DENV4-infected
patients had secondary infections, contrasting with 65%
of DENV1-infected patients. Although ZIKV IgG anti-
bodies were detected in all 8 convalescent-phase samples
of Zika cases, the same samples were also positive for
dengue IgG antibodies, making it impossible to exclude
cross-reactions.
The main limitation of our study was the small number
of ZIKV-confirmed cases. Technical difficulties in ZIKV
diagnosis, especially due to the low viremia during infec-
tion and the cross-reactions with other circulating arbovi-
ruses in tropical and subtropical regions, has hampered
composing large subsets of Zika cases’ samples to be used
in diagnostic test accuracy studies. As another limitation,
we did not perform ZIKV RT-PCR on the acute-phase
samples of all dengue cases to ensure the absence of
co-infection. Even though, sufficient serum was available
to perform RT-PCR in 47 of the 60 dengue cases, and
none of them yielded a positive result. Considering that
our dengue case selection specifically included patients
with infections that occurred prior to 2012, it is unlikely
that they had a dengue and Zika co-infection or a prior
ZIKV infection, because ZIKV introduction into Brazil
was estimated to have occurred between late 2012 and
early 2013 [23–25]. In addition, prior ZIKV infections in
the study group of blood donors cannot be completely
ruled out because their serum samples were obtained in
December 2013; but, as the ZIKV spread in Salvador was
clearly recognized during a large outbreak in 2015, it is
improbable that these individuals had ZIKV infections be-
fore study enrollment.
Strengths of our study included the use of RT-PCR as a
confirmation criterion for both Zika and dengue cases be-
cause as ZIKV and DENV transmission are endemic in our
setting, a molecular diagnosis ensures a more accurate dis-
tinction between these flaviviruses compared to serologic
diagnosis. In addition, the availability of paired sera pro-
vided a unique opportunity to evaluate the performance of
commercial ZIKV IgM- and IgG-ELISAs in detection of
antibodies in acute- and convalescent-phase samples.
Conclusion
In conclusion, our study revealed a high specificity but
low sensitivity of the Euroimmun ZIKV IgM-ELISA in
an endemic region for both dengue and Zika, as well as
a high specificity of the Euroimmun ZIKV IgG-ELISA in
DENV primary infections contrasting with low specifi-
city in DENV secondary infections. This suggests that
this IgG-ELISA may be more suitable for Zika diagnosis
in travelers returning from non-endemic areas than for
serosurveys in endemic areas. Further studies with larger
well-characterized samples are needed to assess the diag-
nostic accuracy not only of this test, but also of several
others serological ZIKV assays.
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